Program Overview
The First Look Awards are part of the MLSC’s Women’s Health Initiative. This program is a collaboration between the Massachusetts Life Sciences Center (MLSC) and the Mary Horrigan Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital (BWH), Harvard Medical School. The goal of this grant program is to support translational research at Massachusetts research institutions that furthers our understanding of sex and gender differences especially for diseases or conditions that affect women solely, disproportionately, or differentially. The First Look Awards align with the Connors Center First.In.Women Precision Medicine Platform, which seeks to promote translational investigation to ensure that novel therapeutics are developed to optimize health for both women and men.
Up to $250,000 is available for the program, and we anticipate making five awards of up to $50,000 to Massachusetts-based women’s health researchers.
The application period will run from Oct. 3, 2022 to Jan. 12, 2023 at 8 p.m. EST.
Eligibility & Evaluation
Eligible applicants must be a full or part-time faculty at a Massachusetts-based research institution proposing an exploratory project to begin developing translatable solutions for women’s health and furthering our understanding of gender biology.
An external panel of scientists from academia and industry with expertise in women’s health will review applications. There may be a request to meet with our review panel. Those applications will receive a notification of that request.
Please see full list of eligibility requirements and evaluation process.
Resources
Mary Horrigan Connors Center for Women’s Health and Gender Biology
Deliverables, Confidentiality, and General Conditions
Learn more about the Women’s Health Initiative
R.E.D.: Research Equipment Database
Impact on the Ecosystem
Massachusetts recognizes there has been a lack of development in novel solutions to treat conditions that affect women solely, disproportionately, or differently. This impacts not only patients but also employers and the healthcare system. The consequences are profound, with women more likely to have adverse drug reactions than men, and the lack of effective therapies results in reduced quality of life. The Massachusetts Life Sciences Center aims to support and incentivize translational project teams developing research towards the understanding of conditions and development of solutions in this area of need.
Learn more about 2022 First Look awardees, including the principal investigator and the innovative projects.
Connect with us to Learn More
If you have questions regarding the application process, e-mail: WomensHealth@masslifesciences.com with “First Look” in the subject line.